TY - JOUR
T1 - Platelet-derived growth factor inhibitors
T2 - A potential therapeutic approach for ocular neovascularization
AU - Sadiq, Mohammad Ali
AU - Hanout, Mostafa
AU - Sarwar, Salman
AU - Hassan, Muhammad
AU - Agarwal, Aniruddha
AU - Sepah, Yasir Jamal
AU - Do, Diana V.
AU - Nguyen, Quan Dong
N1 - Publisher Copyright:
© 2016 S. Karger AG, Basel.
PY - 2015
Y1 - 2015
N2 - Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.
AB - Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.
UR - http://www.scopus.com/inward/record.url?scp=84947267492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947267492&partnerID=8YFLogxK
U2 - 10.1159/000438953
DO - 10.1159/000438953
M3 - Article
C2 - 26501397
AN - SCOPUS:84947267492
SN - 0250-3751
VL - 55
SP - 310
EP - 316
JO - Developments in Ophthalmology
JF - Developments in Ophthalmology
ER -